-

Patients Suffer as Pfizer Pockets Profits, says AHF

LOS ANGELES--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) rebuked pharmaceutical giant Pfizer today for announcing that it plans to charge $1,400 for a five-day course of the COVID-19 antiviral drug Paxlovid. During the pandemic, the U.S. government only paid $529 for the same drug.

“This is yet another example of rampant drug profiteering off the backs of sick people by Big Pharma. The same drug, with the same efficacy, will suddenly cost nearly three times as much when it reaches the commercial market. Why? So that Pfizer can squeeze as much money out of health plans and the pockets of the uninsured as possible for its shareholders and executives,” said AHF President Michael Weinstein. “Greedy Pfizer is in good company – Gilead charges $3,429 for its five-day COVID-19 treatment. We must prioritize public health and equity over corporate profits. Putting profits before people’s lives and health is not only immoral, it leaves the entire world in danger of another pandemic disaster.”

Pfizer’s Paxlovid and Gilead’s Remdesivir are particularly beneficial for people at a higher risk of developing complications from a COVID-19 infection. These patients are already likely to face higher treatment costs due to hospitalizations and prolonged treatment and recovery periods. The exorbitant prices of these drugs put further strain on the personal finances of affected people and healthcare systems, which are still recovering from the effects of the pandemic.

About AIDS Healthcare Foundation (AHF)

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 1.9 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323 308 1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

AIDS Healthcare Foundation


Release Versions

Contacts

US MEDIA CONTACT:
Ged Kenslea, Senior Director, Communications, AHF
+1 323 308 1833 work +1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

More News From AIDS Healthcare Foundation

AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts

TALLAHASSEE, Fla.--(BUSINESS WIRE)--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts...

After UN HIV Meeting, AHF Calls for Resources to Match Promises

LOS ANGELES--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) welcomed the engagement of Member States at the 2026 United Nations High-Level Meeting on HIV/AIDS, while emphasizing that millions of people living with HIV still do not have access to lifesaving treatment, and an estimated 1.2 million people acquire HIV each year. As governments reaffirm their commitment to ending AIDS as a public health threat, AHF urged that political promises be matched by the resources needed to turn commitmen...

Hantavirus Reveals Latin America Is Unprepared, Warns The Lancet Commentary

MEXICO CITY--(BUSINESS WIRE)--The Latin American Technical Working Group, composed of former health ministers from the region, public health experts, epidemiologists, academics, and civil society representatives, published a new comment in The Lancet arguing that Latin America urgently needs a regional rapid-response platform to prevent, prepare for, and respond to infectious threats. Read the full text in The Lancet here. The comment, written collectively by the Technical Working Group, takes...
Back to Newsroom